These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Beyond the laboratory: clinical implications for statin pleiotropy. Halcox JP; Deanfield JE Circulation; 2004 Jun; 109(21 Suppl 1):II42-8. PubMed ID: 15173062 [TBL] [Abstract][Full Text] [Related]
6. To statin or to non-statin in coronary disease-considering absolute risk is the answer. Rembold CM Atherosclerosis; 2008 Oct; 200(2):447. PubMed ID: 18514660 [No Abstract] [Full Text] [Related]
7. High dose statin therapy for all patients with coronary artery disease? Knobler H Isr Med Assoc J; 2005 Nov; 7(11):736-8. PubMed ID: 16308999 [No Abstract] [Full Text] [Related]
8. Incorporating the new lipid guidelines into practice. Spear S JAAPA; 2014 Jun; 27(6):11. PubMed ID: 24803202 [No Abstract] [Full Text] [Related]
9. [Strengthening the role of statin therapy in atherosclerosis for the prevention and treatment of cerebrovascular disease]. Liu LP; Wang YJ Zhonghua Nei Ke Za Zhi; 2011 Apr; 50(4):275-7. PubMed ID: 21600141 [No Abstract] [Full Text] [Related]
10. Through the looking glass: an angioscopic view of the effect of statin therapy on coronary artery plaques. Tawakol A; Muller J J Am Coll Cardiol; 2003 Aug; 42(4):687-9. PubMed ID: 12932602 [No Abstract] [Full Text] [Related]
11. Atherosclerosis or atheroscleritis: what's in a name? Simon Ha Cardiology; 2002; 98(3):111-2. PubMed ID: 12417807 [No Abstract] [Full Text] [Related]
12. Statins, cholesterol, and the prevention of coronary heart disease. Freeman MW FASEB J; 2006 Feb; 20(2):200-1. PubMed ID: 16449790 [No Abstract] [Full Text] [Related]
17. The role of statin therapy in patients with lower vascular risk. Keech AC; Fulcher JR; Simes J Med J Aust; 2012 Aug; 197(3):130-1. PubMed ID: 22860773 [No Abstract] [Full Text] [Related]
18. Atheroma progression in hyporesponders to statin therapy. Kataoka Y; St John J; Wolski K; Uno K; Puri R; Tuzcu EM; Nissen SE; Nicholls SJ Arterioscler Thromb Vasc Biol; 2015 Apr; 35(4):990-5. PubMed ID: 25722430 [TBL] [Abstract][Full Text] [Related]
19. [HMG-CoA reductase inhibitors: a brief review of their pharmacological properties and clinical efficacy in cardiovascular disease]. da Silva PM Rev Port Cardiol; 1999 Jan; 18(1):65-76. PubMed ID: 10091528 [TBL] [Abstract][Full Text] [Related]
20. Intermolecular differences of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors contribute to distinct pharmacologic and pleiotropic actions. Mason RP; Walter MF; Day CA; Jacob RF Am J Cardiol; 2005 Sep; 96(5A):11F-23F. PubMed ID: 16126019 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]